# EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy

> **NCT05998863** · PHASE3 · RECRUITING · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 56 (estimated)

## Conditions studied

- Osteoporosis
- Hypomagnesemia

## Interventions

- **DRUG:** EffCaMgCit
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05998863
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-19
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2025-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05998863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05998863, "EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT05998863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*